Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
3,269,468
-
Share change
-
+621,094
-
Total reported value
-
$2,289,000
-
Price per share
-
$0.70
-
Number of holders
-
10
-
Value change
-
+$436,199
-
Number of buys
-
3
-
Number of sells
-
2
Institutional Holders of MABVAX THERAPEUTICS HLDGS IN - COM NEW (MBVX) as of Q4 2017
As of 31 Dec 2017,
MABVAX THERAPEUTICS HLDGS IN - COM NEW (MBVX) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,269,468 shares.
The largest 10 holders included
Cambridge Investment Research Advisors, Inc., Virtu Financial LLC, Biomark Capital Management Co. LLC, BANK OF AMERICA CORP /DE/, UBS Group AG, Lakeview Capital Partners, LLC, TWO SIGMA SECURITIES, LLC, BRIGHTON JONES LLC, Delaney Dennis R, and CLS Investments, LLC.
This page lists
10
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.